转移性去势抵抗性前列腺癌中[177Lu]Lu-PSMA再挑战治疗的疗效与安全性:系统评价与荟萃分析
该系统评价与荟萃分析纳入11项研究共307例转移性去势抵抗性前列腺癌患者,评估[177Lu]Lu-PSMA再挑战治疗的疗效与安全性。汇总分析显示PSA下降超过50%的比例为0.45(95%CI:0.36–0.54),任何PSA下降比例为0.71(95%CI:0.61–0.80),≥3级毒性汇总比例为0.14(95%CI:0.09–0.19)。作者认为再挑战治疗是晚期/终末期mCRPC患者可行且安全的选择,但需前瞻性随机研究确认。
要点
- 再挑战治疗后PSA下降>50%的汇总比例为0.45(95%CI:0.36–0.54),任何PSA下降为0.71(95%CI:0.61–0.80)。
- ≥3级毒性汇总比例为0.14(95%CI:0.09–0.19),102例中44例(43%)出现1–2级口干,未见≥3级口干。
- 作者认为再挑战治疗对晚期/终末期mCRPC可行且安全,但需前瞻性随机研究确认。
核心结论
- 作者认为[177Lu]Lu-PSMA再挑战治疗是晚期/终末期mCRPC患者可行且安全的选择。
- 作者认为[225Ac]Ac-PSMA串联方案可能有助于扩展对[177Lu]Lu-PSMA进展后如何优化结局的理解。
- 作者指出这些发现需在前瞻性随机研究中比较不同再挑战策略加以确认,以定义晚期前列腺癌的最佳序贯和患者选择标准。
研究设计与样本
- 系统评价与荟萃分析,遵循PRISMA指南,检索PubMed、EMBASE和Scopus自建库至2025年3月。
- 最终纳入11项研究共307例患者,其中196例仅接受177Lu-PSMA放射性配体治疗,111例接受177Lu/225Ac-PSMA串联放射性配体治疗。
- 主要终点为PSA下降超过50%的生化反应和任何PSA下降;次要终点为生存结局和治疗相关毒性;采用随机效应模型生成汇总比例。
主要发现
- PSA下降超过50%的汇总比例为0.45(95%CI:0.36–0.54),任何PSA下降的汇总比例为0.71(95%CI:0.61–0.80)。
- 在总共102例患者中,44例(43%)出现1–2级口干,未报告严重口干(≥3级)病例。
- 发生≥3级毒性的汇总比例为0.14(95%CI:0.09–0.19)。
局限性
- 作者指出这些发现需在前瞻性随机研究中比较不同再挑战策略加以确认,以定义晚期前列腺癌的最佳序贯和患者选择标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lutetium-177 PSMA radioligand therapy ([¹⁷⁷Lu]Lu-PSMA-RLT) is an effective treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). Prospective studies reported favourable efficacy and safety outcomes of up to 6 cycles of [¹⁷⁷Lu]Lu-PSMA. This study aimed to evaluate the efficacy and safety of [¹⁷⁷Lu]Lu-PSMA rechallenge therapy in patients with mCRPC who progressed after an initial course of [¹⁷⁷Lu]Lu-PSMA-RLT. METHODS: This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. A systematic search was performed using relevant keywords in PubMed, EMBASE, and Scopus from establishment to March 2025. Primary endpoints included biochemical responses with a decline in prostate-specific antigen (PSA) of more than 50% and any PSA decline. Secondary outcomes included survival outcomes and treatment-related toxicity following rechallenge therapy with [¹⁷⁷Lu]Lu-PSMA. A random-effects model was used to generate pooled proportions through meta-analysis. RESULTS: Eleven studies with 307 patients were included in the final analysis. Of these, 196 received 177Lu-PSMA RLT alone, and 111 received tandem 177Lu/225Ac-PSMA RLT. The pooled proportions of patients with more than a 50% PSA decline and any PSA decline were 0.45 (95% CI: 0.36–0.54) and 0.71 (95% CI: 0.61–0.80), respectively. In a total of 102 patients, 44 (43%) showed low-grade 1–2 xerostomia; however, no cases of serious xerostomia (grade ≥ 3) were reported. Moreover, the pooled proportion of patients experiencing grade ≥ 3 toxicity was 0.14 (95% CI: 0.09–0.19). CONCLUSION: Rechallenge therapy with [¹⁷⁷Lu]Lu-PSMA is a feasible and safe treatment option for late/end mCRPC patients. Tandem approaches with [225Ac]Ac-PSMA may help expand understanding of how to optimize outcomes after [¹⁷⁷Lu]Lu-PSMA progression. However, these findings require confirmation in prospective, randomized studies comparing different rechallenge strategies to define optimal sequencing and patient selection criteria in advanced prostate cancer.
引用
- Belabaci Z, Schmidt L, Sleiay M, et al. Efficacy and safety of rechallenge therapy with [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2025. PMID: 40705094. doi:10.1007/s00259-025-07438-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。